As CDK9 is a master transcription regulator and a potential target in hematologic malignancies, the authors explored PRT2527 as a novel low nanomolar potent CDK9 inhibitor in B-ALL and CLL primary samples. Here, CDK9 is linked to acute lymphoblastic leukemia.